TYRA
Tyra Biosciences, Inc. NASDAQ Listed Sep 15, 2021$32.90
Mkt Cap $1.8B
52w Low $8.75
75.7% of range
52w High $40.65
50d MA $35.88
200d MA $23.18
P/E (TTM)
-16.9x
EV/EBITDA
-12.5x
P/B
7.8x
Debt/Equity
0.0x
ROE
-46.3%
P/FCF
-16.4x
RSI (14)
—
ATR (14)
—
Beta
0.96
50d MA
$35.88
200d MA
$23.18
Avg Volume
1.1M
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
2656 State Street · Carlsbad, CA 92008 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AMC | -0.54 | -0.57 | -5.6% | 32.52 | -3.4% | +1.5% | +6.8% | -2.1% | +1.4% | -3.7% | — |
| Nov 5, 2025 | AMC | -0.50 | -0.50 | +0.0% | 14.82 | -0.6% | -3.6% | +0.3% | +1.3% | +4.3% | +2.3% | — |
| Aug 14, 2025 | AMC | -0.53 | -0.47 | +11.3% | 10.70 | +5.1% | +0.3% | +0.7% | -5.6% | +0.4% | +14.3% | — |
| May 8, 2025 | AMC | -0.49 | -0.47 | +4.1% | 10.07 | -0.3% | +0.2% | +1.7% | -2.7% | -3.1% | +2.0% | — |
| Mar 27, 2025 | AMC | -0.48 | -0.43 | +10.4% | 9.66 | +8.7% | +1.1% | -4.8% | -6.2% | -0.8% | -4.0% | — |
| Nov 7, 2024 | AMC | -0.40 | -0.41 | -2.5% | 17.15 | -2.7% | -6.1% | +0.7% | -1.8% | -1.3% | +3.8% | — |
| Aug 7, 2024 | AMC | -0.41 | -0.32 | +22.0% | 19.50 | +3.2% | +4.3% | -1.3% | +0.7% | +6.3% | +0.4% | — |
| May 9, 2024 | AMC | -0.46 | -0.35 | +23.9% | 17.76 | +2.7% | -2.3% | +6.6% | +0.4% | -0.8% | +3.6% | — |
| Mar 19, 2024 | AMC | -0.48 | -0.53 | -10.4% | 16.10 | +9.4% | +7.9% | -3.7% | -0.1% | -1.5% | -1.9% | — |
| Nov 7, 2023 | AMC | -0.35 | -0.49 | -40.0% | 12.16 | -3.0% | -1.3% | -3.0% | +1.0% | -0.6% | +5.5% | — |
| Aug 10, 2023 | AMC | -0.34 | -0.31 | +8.8% | 15.11 | +0.0% | +1.9% | +0.7% | +0.0% | -3.9% | -4.6% | — |
| May 4, 2023 | AMC | -0.37 | -0.28 | +24.3% | 12.78 | +5.5% | -2.8% | +8.7% | +1.9% | -6.8% | -4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $38.18 | $38.67 | +1.3% | -2.7% | -1.7% | -0.5% | +1.1% | +3.6% |
| Feb 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.99 | $28.07 | +0.3% | +4.0% | +1.0% | +6.6% | +0.8% | +5.4% |
| Feb 13 | Wedbush | Maintains | Outperform → Outperform | — | $29.19 | $29.41 | +0.8% | -4.1% | +4.0% | +1.0% | +6.6% | +0.8% |
| Feb 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $31.02 | $31.72 | +2.3% | +0.7% | -1.5% | -4.3% | +5.2% | -1.6% |
| Feb 3 | Jefferies | Maintains | Buy → Buy | — | $31.02 | $31.72 | +2.3% | +0.7% | -1.5% | -4.3% | +5.2% | -1.6% |
| Jan 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.91 | $31.51 | +1.9% | -1.7% | -0.7% | +4.1% | -1.0% | +4.1% |
| Dec 16 | Wedbush | Maintains | Outperform → Outperform | — | $22.12 | $22.56 | +2.0% | +3.8% | -1.6% | +1.7% | +11.0% | -0.5% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.70 | $11.72 | +0.2% | +0.1% | +2.5% | +5.3% | +1.9% | -4.0% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.57 | $9.53 | -0.4% | +1.6% | +3.4% | -0.5% | -3.9% | +3.1% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.77 | $9.48 | -3.0% | -4.8% | -6.2% | -0.8% | -4.0% | -6.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.19 | $13.40 | +1.6% | -4.5% | +1.6% | -0.1% | +3.1% | -2.7% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.20 | $15.00 | -1.3% | -0.7% | +5.6% | +5.0% | -3.5% | +0.2% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.11 | $16.02 | -0.6% | +0.7% | -1.8% | -1.3% | +3.8% | -5.8% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.89 | $20.28 | +2.0% | -15.0% | -5.6% | +4.4% | -1.7% | +0.2% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.93 | $22.30 | +1.7% | -9.3% | -15.0% | -5.6% | +4.4% | -1.7% |
| Oct 25 | Wedbush | Maintains | Outperform → Outperform | — | $28.61 | $23.98 | -16.2% | -23.3% | -9.3% | -15.0% | -5.6% | +4.4% |
| Oct 18 | BofA Securities | Upgrade | Neutral → Buy | — | $25.98 | $27.00 | +3.9% | +5.2% | +3.8% | -0.7% | +0.3% | +1.3% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.04 | $22.19 | +0.7% | -5.4% | +3.8% | -1.6% | -1.5% | +4.6% |
| Sep 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $23.20 | $24.00 | +3.4% | +3.4% | +1.5% | -3.0% | +0.1% | -1.6% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $19.50 | $20.12 | +3.2% | +4.3% | -1.3% | +0.7% | +6.3% | +0.4% |
| Aug 8 | Wedbush | Maintains | Outperform → Outperform | — | $19.50 | $20.12 | +3.2% | +4.3% | -1.3% | +0.7% | +6.3% | +0.4% |
| Jul 3 | Wedbush | Maintains | Outperform → Outperform | — | $16.70 | $16.83 | +0.8% | +1.6% | +0.8% | +4.0% | +2.4% | -0.5% |
| Jul 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.70 | $16.83 | +0.8% | +1.6% | +0.8% | +4.0% | +2.4% | -0.5% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.70 | $16.83 | +0.8% | +1.6% | +0.8% | +4.0% | +2.4% | -0.5% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.75 | $17.97 | +1.2% | +7.2% | +4.0% | -0.1% | +1.1% | +1.1% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $17.35 | $17.61 | +1.5% | +6.6% | +0.4% | -0.8% | +3.6% | -4.4% |
| May 10 | Wedbush | Maintains | Outperform → Outperform | — | $17.76 | $18.24 | +2.7% | -2.3% | +6.6% | +0.4% | -0.8% | +3.6% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.76 | $18.24 | +2.7% | -2.3% | +6.6% | +0.4% | -0.8% | +3.6% |
| Mar 21 | Wedbush | Maintains | Outperform → Outperform | — | $17.37 | $17.45 | +0.5% | -3.7% | -0.1% | -1.5% | -1.9% | +0.9% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.10 | $17.61 | +9.4% | +7.9% | -3.7% | -0.1% | -1.5% | -1.9% |
| Dec 29 | Wedbush | Maintains | Outperform → Outperform | — | $13.90 | $14.58 | +4.9% | -0.4% | +1.4% | -9.9% | -4.0% | -4.4% |
| Dec 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.45 | $13.96 | +3.8% | +8.3% | -3.9% | -0.7% | -0.4% | +1.4% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.16 | $11.80 | -3.0% | -1.3% | -3.0% | +1.0% | -0.6% | +5.5% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.11 | $15.11 | +0.0% | +1.9% | +0.7% | +0.0% | -3.9% | -4.6% |
| Aug 11 | Wedbush | Maintains | Outperform → Outperform | — | $15.11 | $15.11 | +0.0% | +1.9% | +0.7% | +0.0% | -3.9% | -4.6% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.82 | $14.81 | -0.1% | -2.8% | +1.4% | +1.4% | -3.3% | -2.2% |
| May 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.42 | $12.14 | -2.3% | +8.7% | +1.9% | -6.8% | -4.1% | +1.0% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.78 | $13.48 | +5.5% | -2.8% | +8.7% | +1.9% | -6.8% | -4.1% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.17 | $15.50 | +2.2% | +1.8% | +3.2% | +0.1% | -0.1% | +1.7% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.60 | $14.36 | +5.6% | +10.3% | +1.2% | -0.6% | -19.9% | +7.8% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.77 | $13.11 | +2.7% | -4.3% | -0.7% | +12.1% | +10.3% | +1.2% |
| Feb 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.30 | $13.75 | +3.4% | -0.9% | +2.0% | +0.7% | -3.4% | +7.4% |
| Jun 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.27 | $6.88 | +9.7% | +11.3% | +2.4% | -8.3% | +10.8% | +11.8% |
| Mar 8 | Jefferies | Upgrade | Hold → Buy | — | $10.96 | $11.93 | +8.9% | +3.3% | +6.8% | -7.5% | -1.7% | -3.9% |
| Nov 8 | Jefferies | Downgrade | Buy → Hold | — | $28.39 | $28.95 | +2.0% | +2.3% | -3.0% | -1.6% | +1.7% | -2.3% |
| Oct 11 | Jefferies | Maintains | Buy → Buy | — | $16.26 | $15.95 | -1.9% | -5.3% | +1.7% | +4.6% | -0.7% | +0.4% |
| Oct 11 | BofA Securities | Maintains | Buy → Buy | — | $16.26 | $15.95 | -1.9% | -5.3% | +1.7% | +4.6% | -0.7% | +0.4% |
| Oct 11 | Cowen & Co. | Maintains | Outperform → Outperform | — | $16.26 | $15.95 | -1.9% | -5.3% | +1.7% | +4.6% | -0.7% | +0.4% |
No insider trades available.
8-K
Tyra Biosciences, Inc. -- 8-K Filing
Tyra Biosciences appointed a board member with significant biopharmaceutical experience, including prior roles at Blueprint Medicines (acquired by Sanofi) and other therapeutic companies.
Apr 17
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing content is incomplete metadata/technical specifications rather than substantive financial information about State Street (STT) or Tyra Biosciences (TYRA).
Apr 2
8-K
Tyra Biosciences, Inc. -- 8-K Filing
I cannot provide a meaningful one-sentence analysis because the summary contains only technical XBRL metadata and filing administrative information rather than substantive business news or events affecting Tyra Biosciences investors.
Mar 4
8-K
Tyra Biosciences, Inc. -- 8-K Filing
Tyra Biosciences reported 2025 year-end financial results and corporate progress updates for its FGFR-focused precision medicine pipeline, with CEO Todd Harris emphasizing the company's science-driven development strategy.
Mar 2
Data updated apr 27, 2026 6:20am
· Source: massive.com